A Phase 1 Clinical Study of BW-20805-2-1001 in Healthy Participants

Inclusion Criteria: * Must have given written informed consent and be able to comply with all study requirements * Males or females aged 18 to 60 years old, inclusive, at the time of informed consent. * Body mass index (BMI) ≥18 and ≤32 kg/m2 and body weight ≥50 kg Female participants must be non-pregnant * Male participants with female partners of child-bearing potential must agree to use acceptable methods of contraception from screening until 48 weeks following administration of the study drug Exclusion Criteria: * Any clinically significant chronic medical condition or clinically significant abnormality in physical examination that * Any skin condition and/or tattoo that may interfere with the evaluation of safety at the injection site * Hospitalization for any reason within 60 days prior to screening. * Presence of carcinoma and history of carcinoma * Any clinically significant acute condition * Systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg after at least 5 minutes resting * Clinical laboratory findings outside of range are deemed clinically significant by the investigator at screening * Participants with ANY in clinical laboratory tests at screening or Day-1. * History of bleeding diathesis or clinically significant hemorrhagic disorders Positive for hepatitis B surface antigen * Single 12-lead ECG with clinically significant abnormalities at screening or Day -1 * Use of an investigation agent or device within 30 days or 5 half-lives (whi…